AR063438A1 - Derivados de eter como moduladores duales de los receptores de 5-ht2a y d3 - Google Patents

Derivados de eter como moduladores duales de los receptores de 5-ht2a y d3

Info

Publication number
AR063438A1
AR063438A1 ARP070104779A ARP070104779A AR063438A1 AR 063438 A1 AR063438 A1 AR 063438A1 AR P070104779 A ARP070104779 A AR P070104779A AR P070104779 A ARP070104779 A AR P070104779A AR 063438 A1 AR063438 A1 AR 063438A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
alkyl
halogen
aryl
alkoxy
Prior art date
Application number
ARP070104779A
Other languages
English (en)
Inventor
Luca Gobbi
Georg Jaeschke
Sarmiento Rosa Maria Rodriguez
Lucinda Steward
Olivier Roche
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38962066&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR063438(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR063438A1 publication Critical patent/AR063438A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Se refiere a un proceso para su obtencion, a sus sales farmacéuticamente aceptables, destinados a la fabricacion de medicamentos para el tratamiento o la prevencion de trastornos cognitivos, adiccion a las drogas, depresion, ansiedad, dependencia de las drogas, demencias, desequilibro de la memoria, trastornos psicoticos, incluida la esquizofrenia, trastornos esquizoafectivos, enfermedad bipolar, manías, depresion psicotica y psicosis que comprenden la paranoia y los delirios. Reivindicacion 1: Compuestos de la formula general (1) en la que A es arilo o heteroarilo de 5 a 12 eslabones, que están opcionalmente sustituidos por: halogeno; ciano; alquilo C1-6 opcionalmente sustituido por ciano o alcoxi C1-6; alcoxi C1-6; o -S(O)2-alquilo C1- 6; R1 es alquilo C1-6 opcionalmente sustituido por: uno o más halogeno, alcoxi C1-6 o arilo opcionalmente sustituido por halogeno; o es cicloalquilo C3-10 opcionalmente sustituido por uno o más Ra; o es heterocicloalquilo de 5 a 12 eslabones opcionalmente sustituido por uno o más Ra; o es arilo opcionalmente sustituido por uno o más Ra; o es heteroarilo de 5 a 12 eslabones opcionalmente sustituido por uno o más Ra; o es -NRbRc, en el que Rb es H o alquilo C1-6 y en el que Rc es H, alquilo C1-6 o arilo opcionalmente sustituido por uno o más Ra; en el que Ra se elige entre: halogeno; -S(O)2-alquilo C1-6; ciano; oxo; alquilo C1-6 opcionalmente sustituido por arilo, que está sustituido por halogeno; haloalquilo C1-6; haloalcoxi C1-6; alcoxi C1-6 opcionalmente sustituido por heteroarilo de 5 o 6 eslabones, que está opcionalmente sustituido por alquilo C1-6; -NH(CO)-alquilo C1-6; heterocicloalquilo de 5 o 6 eslabones; o heteroarilo de 5 o 6 eslabones opcionalmente sustituido por alquilo C1-6 u oxo; R2 es H u OH; así como sus sales farmacéuticamente aceptables.
ARP070104779A 2006-10-31 2007-10-29 Derivados de eter como moduladores duales de los receptores de 5-ht2a y d3 AR063438A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06123274 2006-10-31

Publications (1)

Publication Number Publication Date
AR063438A1 true AR063438A1 (es) 2009-01-28

Family

ID=38962066

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070104779A AR063438A1 (es) 2006-10-31 2007-10-29 Derivados de eter como moduladores duales de los receptores de 5-ht2a y d3

Country Status (18)

Country Link
US (1) US7795437B2 (es)
EP (1) EP2079693B1 (es)
JP (1) JP5087631B2 (es)
KR (1) KR101114651B1 (es)
CN (1) CN101535258B (es)
AR (1) AR063438A1 (es)
AU (1) AU2007316249B2 (es)
BR (1) BRPI0718127A2 (es)
CA (1) CA2667511A1 (es)
CL (1) CL2007003110A1 (es)
ES (1) ES2401663T3 (es)
IL (1) IL198157A0 (es)
MX (1) MX2009004615A (es)
NO (1) NO20091675L (es)
PE (1) PE20081342A1 (es)
RU (1) RU2009116509A (es)
TW (1) TW200826940A (es)
WO (1) WO2008052899A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2183245B1 (en) * 2007-07-26 2014-07-09 F. Hoffmann-La Roche AG Dual modulators of 5-ht2a and d3 receptors
US8273900B2 (en) 2008-08-07 2012-09-25 Novartis Ag Organic compounds
US20110117214A1 (en) * 2009-11-16 2011-05-19 Auspex Pharmaceuticals, Inc. Cyclohexyl urea modulators of d2 receptors and/or d3 receptors
US8877778B2 (en) 2010-12-15 2014-11-04 Hoffmann-La Roche Inc. Benzofurane compounds
US8722683B2 (en) * 2011-02-17 2014-05-13 Hoffmann La-Roche Inc. Benzodioxole piperazine compounds
US8921397B2 (en) 2011-05-04 2014-12-30 Hoffmann-La Roche Inc. Benzofurane-piperidine compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1514718A (en) 1974-08-15 1978-06-21 Ferrosan Ab Diphenyl-butylpiperidines
US4024264A (en) * 1974-08-15 1977-05-17 Ab Ferrosan Diphenylbutylpiperidines
JP2860689B2 (ja) 1990-03-14 1999-02-24 第一製薬株式会社 ピリミジン誘導体
US5229400A (en) 1990-10-05 1993-07-20 Ajinomoto Co., Inc. Piperidine compounds and their use as antiarrhythmic agents
PL350904A1 (en) 1999-03-26 2003-02-10 Astrazeneca Ab Novel compounds
HU227543B1 (en) * 2001-09-28 2011-08-29 Richter Gedeon Nyrt N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them
HUP0103986A2 (hu) 2001-09-28 2003-06-28 Richter Gedeon Vegyészeti Gyár Rt. Új karbonsavamid szerkezetet tartalmazó piperidinil vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
EP1499607B1 (en) 2001-12-04 2005-12-07 Actelion Pharmaceuticals Ltd. 4-(piperidyl- and pyrrolidyl-alkyl-ureido)-quinolines as urotensin ii receptor antagonists
EP1348434A1 (en) 2002-03-27 2003-10-01 Fujisawa Deutschland GmbH Use of pyridyl amides as inhibitors of angiogenesis
US7186725B2 (en) 2003-01-03 2007-03-06 Genzyme Corporation Anti-inflammatory compositions and methods
HU227534B1 (en) 2003-08-04 2011-08-29 Richter Gedeon Nyrt (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
KR20090075848A (ko) 2009-07-09
WO2008052899A1 (en) 2008-05-08
CL2007003110A1 (es) 2008-06-13
US7795437B2 (en) 2010-09-14
EP2079693A1 (en) 2009-07-22
MX2009004615A (es) 2009-05-22
PE20081342A1 (es) 2008-09-18
CN101535258B (zh) 2012-12-05
TW200826940A (en) 2008-07-01
RU2009116509A (ru) 2010-12-10
CN101535258A (zh) 2009-09-16
ES2401663T3 (es) 2013-04-23
NO20091675L (no) 2009-05-28
US20080103174A1 (en) 2008-05-01
AU2007316249B2 (en) 2013-01-24
CA2667511A1 (en) 2008-05-08
JP5087631B2 (ja) 2012-12-05
EP2079693B1 (en) 2013-02-27
JP2010508319A (ja) 2010-03-18
IL198157A0 (en) 2009-12-24
AU2007316249A1 (en) 2008-05-08
BRPI0718127A2 (pt) 2014-02-18
KR101114651B1 (ko) 2012-06-12

Similar Documents

Publication Publication Date Title
AR073622A1 (es) Compuestos de benzo[d]isoxazol moduladores de receptores de dopamina d3 y de la serotonina 5-ht2a, proceso para prepararlos, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento de trastornos psicoticos
AR063438A1 (es) Derivados de eter como moduladores duales de los receptores de 5-ht2a y d3
AR067662A1 (es) Derivados de benzo[d]isoxazol-3-il-piperidina, medicamentos que los contienen y usos terapeuticos para enfermedades asociadas al sistema nervioso.
AR048289A1 (es) Eteres de anillos imidazo sulfona sustituidos.
AR076380A1 (es) Azetidinil diamidas inhibidoras de monoacilglicerol lipasa(mgl), composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento de enfermedades y patologias que incluyen dolor inflamatorio.
PE20121127A1 (es) Derivados de piridina y pirazina como moduladores de cinasa de proteina
AR078756A1 (es) Moduladores alostericos positivos (map)
AR050186A1 (es) Derivados de amino-piperidina, su preparacion y su aplicacion en terapeutica.
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
PE20160844A1 (es) Compuestos triciclicos como agentes anticancerigenos
AR054024A1 (es) Derivados de piridina -3- carboxamida como agonistas inversos de cb1
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR073565A1 (es) Derivados de bencimidazol, procesos de preparacion y composiciones farmaceuticas que los contienen
AR050365A1 (es) Compuestos inhibidores de multi- quinasa pirrolopirimidina aril- amino sustituidos.
AR070395A1 (es) Derivados de 4,5-dihidro-oxazol-2-il- amina
PE20091687A1 (es) Derivados de piridina o pirazina como inhibidores de cinasa-pi-3
PE20080263A1 (es) Compuestos de pirrolo-pirimidina y sus usos
AR058984A1 (es) Derivados de ciclohexil piperazinil metanona
PE20061298A1 (es) Compuestos derivados de dihidrobenzofurano como agonistas del receptor de serotonina 5-ht2c
AR066107A1 (es) Derivados de triazolopiridin - carboxamidas y triazolopirimidin-carboxamidas, su preparacion y su aplicacion en terapeutica como inhibidores de la enzimamonoacil glicerol lipasa y composiciones qu los contienen.
AR058728A1 (es) Derivados de aril-isoxazol-4-il-imidazo[1,5-a]piridina, metodo de preparacion,medicamentos que los contienen y usos en el tratamiento de trastornos cognitivos.
CY1117862T1 (el) Ετεροκυκλικες ενωσεις βενζοδιοξολιου ή βενζοδιοξεπινης ως αναστολεις φωσφοδιεστερασης
AR052314A1 (es) Compuestos de tienopiridinona como agonistas del receptor 5-ht4
UY31376A1 (es) Derivados de quinazolinadiona, su preparacion y sus aplicaciones terapéuticas
AR064831A1 (es) Derivados de espiropiperidina-glicinamida

Legal Events

Date Code Title Description
FB Suspension of granting procedure